Biologica Technologies® showcases AMP aesthetic™ at Plastic Surgery The Meeting 2017

CARLSBAD, Calif., Oct. 6, 2017 /PRNewswire/ -- Biologica Technologies, developers and marketers of Allofill®, announced today that they will be introducing AMP aesthetic at the upcoming Plastic Surgery The Meeting, the annual conference hosted by the American Society of Plastic Surgeons (ASPS).

AMP aesthetic is the first product of its kind, an allogeneic-derived growth factor that can be used in the same manner as platelet rich plasma (PRP). The product contains a full cascade of growth factors, including but not limited to; PDGF, TGF-β1, and VEGF. In comparison with market leading PRP systems and the PRP processed, AMP aesthetic possesses sufficiently higher growth factor amounts. Additionally, when AMP aesthetic is combined with autologous fat transfer (AFT), early data has exhibited higher graft retention than AFT alone.

"AMP aesthetic continues our company's commitment of bringing cutting edge tissue-based technologies to the field of aesthetics," stated Scott Cadotte, Vice President of Sales & Marketing of Biologica Technologies. "It provides a cost-effective 'off the shelf' option for plastic surgeons and their patients."

About Biologica Technologies
Founded in 2015, Biologica Technologies is a privately-held company fully dedicated to improving patients' lives and the health care providers' experience through innovative biologic solutions. Their first aesthetic product, Allofill, is an adipose-derived filler containing naturally occurring growth factors that can be used to fill soft-tissue defects as a noninvasive alternative to autologous fat grafting. The company is headquartered in Carlsbad, CA.

Related Links
www.biologicatechnologies.com
www.allofill.com

SOURCE Biologica Technologies

Related Links

http://www.biologicatechnologies.com